Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lut Overbergh

Showing results (91-100 of 97) with videos related to

Pageof 10
Sort By:
You have reached the last page of results.This site can display upto 97 results.
BMJ Open|December 8, 2021
Study protocol: Minimum effective low dose: anti-human thymocyte globulin (MELD-ATG): phase II, dose ranging, efficacy study of antithymocyte globulin (ATG) within 6 weeks of diagnosis of type 1 diabetesCharlotte S Wilhelm-Benartzi, Sarah E Miller, Sylvaine Bruggraber, et al.
Diabetes|September 25, 2021
CD8<sup>+</sup> T Cells Variably Recognize Native Versus Citrullinated GRP78 Epitopes in Type 1 DiabetesMarie Eliane Azoury, Fatoumata Samassa, Mijke Buitinga, et al.
Nature Medicine|November 8, 2016
Analysis of self-antigen specificity of islet-infiltrating T cells from human donors with type 1 diabetesJenny Aurielle B Babon, Megan E DeNicola, David M Blodgett, et al.
Diabetologia|May 1, 2026
Psychosocial implications, acceptability and ethics of screening for paediatric type 1 diabetes: a systematic review and mixed methods evidence synthesisLauren M Quinn, David Stanley, Francesca Milano, et al.
Nature Genetics|March 22, 2016
Genetic predisposition for beta cell fragility underlies type 1 and type 2 diabetesJames Dooley, Lei Tian, Susann Schonefeldt, et al.
Lancet (London, England)|September 21, 2025
Minimum effective low dose of antithymocyte globulin in people aged 5-25 years with recent-onset stage 3 type 1 diabetes (MELD-ATG): a phase 2, multicentre, double-blind, randomised, placebo-controlled, adaptive dose-ranging trialChantal Mathieu, Julie Wych, A Emile J Hendriks, et al.
Diabetes/Metabolism Research and Reviews|July 4, 2024
Multi-omics analysis reveals drivers of loss of β-cell function after newly diagnosed autoimmune type 1 diabetes: An INNODIA multicenter studyJose Juan Almagro Armenteros, Caroline Brorsson, Christian Holm Johansen, et al.
Pageof 10

Showing results (91-100 of 97) with videos related to

Sort By:
Pageof 10
You have reached the last page of results.This site can display upto 97 results.
BMJ Open|December 8, 2021
Study protocol: Minimum effective low dose: anti-human thymocyte globulin (MELD-ATG): phase II, dose ranging, efficacy study of antithymocyte globulin (ATG) within 6 weeks of diagnosis of type 1 diabetesCharlotte S Wilhelm-Benartzi, Sarah E Miller, Sylvaine Bruggraber, et al.
Diabetes|September 25, 2021
CD8<sup>+</sup> T Cells Variably Recognize Native Versus Citrullinated GRP78 Epitopes in Type 1 DiabetesMarie Eliane Azoury, Fatoumata Samassa, Mijke Buitinga, et al.
Nature Medicine|November 8, 2016
Analysis of self-antigen specificity of islet-infiltrating T cells from human donors with type 1 diabetesJenny Aurielle B Babon, Megan E DeNicola, David M Blodgett, et al.
Diabetologia|May 1, 2026
Psychosocial implications, acceptability and ethics of screening for paediatric type 1 diabetes: a systematic review and mixed methods evidence synthesisLauren M Quinn, David Stanley, Francesca Milano, et al.
Nature Genetics|March 22, 2016
Genetic predisposition for beta cell fragility underlies type 1 and type 2 diabetesJames Dooley, Lei Tian, Susann Schonefeldt, et al.
Lancet (London, England)|September 21, 2025
Minimum effective low dose of antithymocyte globulin in people aged 5-25 years with recent-onset stage 3 type 1 diabetes (MELD-ATG): a phase 2, multicentre, double-blind, randomised, placebo-controlled, adaptive dose-ranging trialChantal Mathieu, Julie Wych, A Emile J Hendriks, et al.
Diabetes/Metabolism Research and Reviews|July 4, 2024
Multi-omics analysis reveals drivers of loss of β-cell function after newly diagnosed autoimmune type 1 diabetes: An INNODIA multicenter studyJose Juan Almagro Armenteros, Caroline Brorsson, Christian Holm Johansen, et al.
Pageof 10